Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

Rosneft increased gas production by 7%

8/30/24 ROSN

Ingrad reported for 6 months of 2024 by IFRS

8/30/24 INGR

Fesco reports for 6 months of 2024 by IFRS

8/30/24 FESH

Rosneft reported for 6 months of 2024 by IFRS

8/30/24 ROSN

Sistema reported for 6 months of 2024 by IFRS

8/30/24 AFKS

Bashneft reports for 6 months of 2024 by IFRS

8/30/24 BANE

PIK reported for 6 months of 2024 by IFRS

8/30/24 PIKK

Pharmacy Chain 36.6 reported for 6 months of 2024 by IFRS

8/30/24 APTK

Krasny Oktyabr reported for 6 months of 2024 by IFRS

8/30/24 KROT

Globaltrak reported for 6 months of 2024 by IFRS

8/29/24 GTRK